Therapeutic Areas
Advancing Health Through Science and Strategic Partnerships
Our journey began in 2013 under the name TRPharm, and in 2025, we continue as Inpharmus, in line with our vision of becoming a global healthcare company.
Contact UsRare Diseases
Although each rare disease affects only a small number of individuals, collectively they impact a large and growing population worldwide. Today, more than 6,000 rare disordershave been identified, and the number continues to rise as diagnostic technologies improve andnovel diseases are continuously described in the medical literature. This shift has led to an important perspective: rare diseases may be individually uncommon, but together they represent a significant public health challenge.
The definition of “rare” can also vary across regions, a disorder may be considered rare in onegeography yet more prevalent in another due to founder mutations, genetic background, environmental factors, or increased clinical awareness.
Clinical Overview
Rare diseases frequently originate from genetic, immunological, metabolic, orneuroinflammatory mechanisms. While many genetic diseases belong to the rare diseasespectrum, not all rare diseases are solely genetic, some arise from immune dysregulation, autoinflammatory pathways or complex metabolic processes.
Due to their low prevalence, patients often experience a prolonged diagnostic journey, alsoreferred to as the “diagnostic odyssey”, which may span several years. Limited diseaseawareness, fragmented care pathways and insufficient access to specialized centers contributesignificantly to diagnostic delay.
The impact of rare diseases extends beyond medical concerns , psychological, social andeconomic challenges also affecting patients and their families are widely reported.e
Inpharmus Mission in Rare Diseases
Inpharmus, guided by scientific approaches targeting neurological, immunological, andmetabolic mechanisms underlying rare diseases, aims to support earlier diagnosis, strengthentreatment access, and ensure the delivery of effective therapies to patients through innovativesolutions.
Inpharmus Focus Areas
Inpharmus is committed to supporting physicians and pharmacists in the diagnosis and treatment of rare neurological, metabolic, autoinflammatory and immune-mediated disorders, each generally encountered in fewer than 1 in 50,000 individuals. Our approach is rooted in medical science and clinical collaboration, incorporating:
✦ Support for early and accurate diagnosis
✦ Evidence-based therapeutic strategies
✦ Collaboration with specialized centers
✦ Scientific education and awareness initiatives
✦ Continuous partnership with healthcare professionals
Important Notice
All content on this website is intended exclusively for physicians and pharmacists forinformational and educational purposes. The information provided does not replace medical advice. Diagnosis and treatment decisionsmust be made solely by qualified healthcare professionals.
Hematology
The hematologic system plays a vital role in oxygen transport, immune defense, coagulationand cellular homeostasis. Disorders affecting this system may arise from defects in blood cellproduction, proliferation, differentiation or immune regulation. The clinical spectrum rangesfrom acquired conditions to genetically driven immune dysregulation syndromes that requireadvanced and multidisciplinary care.
In modern hematology, increasing attention is given to:
Many of these conditions present with severe and rapidly progressive disease courses, whereearly recognition, immunological assessment and timely therapeutic intervention are essentialfor patient survival. Research increasingly highlights the importance of cytokinedysregulation, genetic susceptibility and immune system overactivation in the pathogenesis of selected hematologic disorders.
Inpharmus Mission in Hematology
Inpharmus is dedicated to supporting healthcare professionals in managing complexhematologic conditions through scientific collaboration and evidence-based approaches. Thecompany aims to enhance diagnostic accuracy, promote immune and cellular mechanismawareness and strengthen access to innovative treatment strategies for patients withchallenging hematologic clinical presentations.
Important Notice
All content on this website is intended exclusively for physicians and pharmacists forinformational and educational purposes. The information provided does not replace medical advice. Diagnosis and treatment decisionsmust be made by qualified healthcare professionals.
Rheumatology
Rheumatic diseases include a broad spectrum of autoimmune and inflammatory disorders thatinvolve the joints, connective tissues, muscles and systemic immune pathways. Theseconditions often arise from an imbalance or overactivation of the immune system, which maylead to chronic inflammation, tissue damage and functional impairment.
While many rheumatic disorders affect the musculoskeletal system, it is now recognized thatthey may also involve multi-organ inflammation and hematologic immune activation, potentially progressing to severe hyperinflammatory states in selected clinical scenarios. Earlyrecognition of such immune dysregulation is essential to prevent organ damage and achievefavorable outcomes.
The current focus areas in rheumatology include:
Inpharmus supports healthcare professionals in rheumatology by promoting scientificunderstanding, improving diagnostic awareness and contributing to therapeutic advancementsin immune-mediated and inflammation-driven disorders. The company collaborates withinclinical and scientific frameworks to enhance access to innovative approaches while fullyadhering to ethical and regulatory standards.
Important Notice
All content on this website is intended exclusively for physicians and pharmacists forinformational and educational purposes. The information provided does not replace medical advice. Diagnosis and treatment decisionsmust be made by qualified healthcare professionals.
Oncology
The human body is governed by a complex regulatory system that controls cell growth, maturation, proliferation and programmed cell death (apoptosis) beginning as early as the in-utero stage of life. Cancer develops when these regulatory mechanisms are disrupted byaccumulated genetic, epigenetic or molecular alterations, leading to uncontrolled proliferationof dysfunctional cells.
Cancer may occur in any tissue or organ of the body. Multiple cancer subtypes can emergefrom the same tissue depending on genetic drivers, signaling pathways and tumormicroenvironment characteristics. Despite this biological diversity, a core hallmark shared byall cancers is abnormal and uncontrolled cell division.
Contemporary oncology research increasingly focuses on:
Inpharmus aims to contribute to oncological care by supporting scientific awareness, improving diagnostic pathways and facilitating evidence-based clinical decision making. Within the framework of ethical and regulatory standards, the company collaborates withspecialists to deepen the understanding of tumor mechanisms and support access toinnovative approaches in challenging cancer types.
Important Notice
All content on this website is intended exclusively for physicians and pharmacists forinformational and educational purposes. The information provided does not replace medical advice. Diagnosis and treatment decisionsmust be made solely by qualified healthcare professionals.